Mirae Asset Global Investments’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Mirae Asset Global Investments’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-18,604	Closed	-$2M	–	2733
2023 Q1	$2M	Buy	18,604 +2,553	+16%	+$294K	﹤0.01%	1204
2022 Q4	$1.77M	Buy	16,051 +2,241	+16%	+$145K	﹤0.01%	1210
2022 Q3	$815K	Buy	13,810 +3,761	+37%	+$172K	﹤0.01%	1599
2022 Q2	$283K	Buy	+10,049	New	+$291K	﹤0.01%	2017

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Mirae Asset Global Investments's RXDX Position: Q2 2023 in Review

Mirae Asset Global Investments sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 18,604 shares — an estimated $2M sold.

Mirae Asset Global Investments first reported a position in RXDX in Q2 2022 and held it in 4 quarters. The position peaked at $2M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Mirae Asset Global Investments reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Mirae Asset Global Investments sold 18,604 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $2M.
Mirae Asset Global Investments first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
Mirae Asset Global Investments's Prometheus Biosciences, Inc. Common Stock position peaked at $2M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Mirae Asset Global Investments's 13F filing for Q2 2023, filed 10 Aug 2023.